Ontology highlight
ABSTRACT: Aim
To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).Methods
Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-RNA suppressed at EOT but detectable thereafter). Sequencing analysis was performed to describe prevalence of drug class-specific RAS. Factors associated with failure were determined using logistic regression models.Results
Among 559 patients, 77% had suppressed plasma HIV-RNA < 50 copies/mL at DAA treatment initiation, 41% were cirrhotic, and 68% were HCV treatment-experienced. Virological treatment failures occurred in 22 patients and were mainly relapses (17, 77%) then undefined failures (3, 14%) and non-responses (2, 9%). Mean treatment duration was 16 wk overall. Post-treatment NS3, NS5A or NS5B RAS were detected in 10/14 patients with samples available for sequencing analysis. After adjustment for age, sex, ribavirin use, HCV genotype and treatment duration, low platelet count was the only factor significantly associated with a higher risk of failure (OR: 6.5; 95%CI: 1.8-22.6).Conclusion
Only 3.9% HIV-HCV coinfected patients failed DAA regimens and RAS were found in 70% of those failing. Low platelet count was independently associated with virological failure.
SUBMITTER: Salmon D
PROVIDER: S-EPMC6280155 | biostudies-literature | 2018 Nov
REPOSITORIES: biostudies-literature
Salmon Dominique D Trimoulet Pascale P Gilbert Camille C Solas Caroline C Lafourcade Eva E Chas Julie J Piroth Lionel L Lacombe Karine K Katlama Christine C Peytavin Gilles G Aumaitre Hugues H Alric Laurent L Boué François F Morlat Philippe P Poizot-Martin Isabelle I Billaud Eric E Rosenthal Eric E Naqvi Alissa A Miailhes Patrick P Bani-Sadr Firouzé F Esterle Laure L Carrieri Patrizia P Dabis François F Sogni Philippe P Wittkop Linda L
World journal of hepatology 20181101 11
<h4>Aim</h4>To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).<h4>Methods</h4>Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV- ...[more]